DVAX

Heplisav-B

Hepatitis B Vaccine

Stage (next event)

Expected Date

Quarterly Sales (Approved)

February 24, 2021 (Est)

Catalyst Info & Data Links

TITLE: Heplisav-B, a Hepatitis B Vaccine Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Approved Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 24, 2021 (Est)


PRIOR DATA

PRESS RELEASE

MECHANISM OF ACTION

  • Unlike traditional 3-dose vaccines that use an alum adjuvant with no specific cellular response, HEPLISAV-B combines a yeast-derived recombinant hepatitis B surface antigen (HBsAg) with the proprietary adjuvant, 1018, to activate Toll-like receptor 9 (TLR9) expressed on first-responder immune cells for direct immune stimulation.

  • The proprietary antigen is taken up by the TLR9-expressing antigen-presenting cell to trigger a cascade of robust immunostimulatory responses. This may induce a highly specific, helper T-cell response to generate memory T and B cells.


Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ASCO 2018 Amp Noteworthy Abstracts

AACR 2018 Amp Up

March 2018 Amp Up

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon